{
    "id": 2552,
    "fullName": "PTEN del",
    "impact": "deletion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "PTEN del indicates a deletion of the PTEN gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5728,
        "geneSymbol": "PTEN",
        "terms": [
            "PTEN",
            "10q23del",
            "BZS",
            "CWS1",
            "DEC",
            "GLM2",
            "MHAM",
            "MMAC1",
            "PTEN1",
            "PTENbeta",
            "TEP1"
        ]
    },
    "variant": "del",
    "createDate": "11/07/2014",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3769,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including prostate cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 992,
                "therapyName": "AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4118,
                    "pubMedId": null,
                    "title": "Phase I study of the PI3K?/? inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/CT329.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3009,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 3070,
                "therapyName": "Pictilisib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                },
                {
                    "id": 3569,
                    "pubMedId": 9661880,
                    "title": "Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9661880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2700,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3425,
                    "pubMedId": 23565244,
                    "title": "PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23565244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2972,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human prostate cancer cell line with deletion of PTEN (PMID: 21558396).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5091,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in minor inhibition of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 3749,
                "therapyName": "Alpelisib + AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5093,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and Xtandi (enzalutamide) combination treatment resulted in suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 3752,
                "therapyName": "AZD8186 + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8965,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cell line xenograft models with PTEN deletion demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 191,
                    "pubMedId": 24141624,
                    "title": "Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24141624"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4498,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 693,
                "therapyName": "CC-223",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3493,
                    "pubMedId": 26177599,
                    "title": "A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26177599"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2509,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a human prostate cancer cell line harboring a PTEN deletion in culture, and inhibited PI3K/MTOR signaling and tumor growth in xenograft models (PMID: 23270925).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 960,
                "therapyName": "VS-5584",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 351,
                    "pubMedId": 23270925,
                    "title": "VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23270925"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2971,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 induced tumor regression in xenograft models of a human stomach cancer cell line with deletion of PTEN (PMID: 21558396).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3138,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human prostate cancer cells harboring PTEN deletion in culture (PMID: 21325073, PMID: 14737113).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3644,
                    "pubMedId": 14737113,
                    "title": "PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14737113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5092,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186, Alpelisib (BYL719), and Xtandi (enzalutamide) combination treatment resulted in near-complete suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 3750,
                "therapyName": "Alpelisib + AZD8186 + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 106,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-04691502 inhibited tumor growth in PTEN-deleted non-small cell lung cancer cell line xenograft models (PMID: 21750219).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 865,
                "therapyName": "PF-04691502",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 226,
                    "pubMedId": 21750219,
                    "title": "PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21750219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5867,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells homozygous for PTEN deletion were resistant to Taselisib (GDC-0032) in culture (PMID: 26589432).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4291,
                    "pubMedId": 26589432,
                    "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26589432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3731,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, patients with advanced solid tumors deficient in PTEN lacked benefit from GSK2636771 (PMID: 26117819).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4036,
                    "pubMedId": 26117819,
                    "title": "Drugging PI3K in cancer: refining targets and therapeutic strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26117819"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5176,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bladder cancer cells with PTEN deletion were sensitive to Glucophage (metformin) in culture, resulting in inhibition of cell growth (PMID: 26921394).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4943,
                    "pubMedId": 26921394,
                    "title": "High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with \u223c240-Fold Higher Drug Concentration in Urine than Serum.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26921394"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3732,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, one patient with PIK3CB L1049R and PTEN deficient prostate cancer had a favorable response to GSK2636771 for 33 weeks (PMID: 26117819).",
            "molecularProfile": {
                "id": 15028,
                "profileName": "PIK3CB L1049R PTEN del"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4036,
                    "pubMedId": 26117819,
                    "title": "Drugging PI3K in cancer: refining targets and therapeutic strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26117819"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3733,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, one patient with PIK3CB amplification and PTEN deficient prostate cancer had a partial response to GSK2636771 (PMID: 26117819).",
            "molecularProfile": {
                "id": 15029,
                "profileName": "PIK3CB amp PTEN del"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4036,
                    "pubMedId": 26117819,
                    "title": "Drugging PI3K in cancer: refining targets and therapeutic strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26117819"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7044,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Adavosertib (MK-1775) induced apoptosis of mouse proneural glioblastoma cells lacking TP53 and PTEN and over expressing PDGFB in cell culture (PMID: 27196784).",
            "molecularProfile": {
                "id": 24369,
                "profileName": "PDGFB over exp PTEN del TP53 del"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 50804,
                "name": "glioblastoma proneural subtype",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6050,
                    "pubMedId": 27196784,
                    "title": "Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196784"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7235,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Actos (pioglitazone) treatment reduced thyroid size, normalized thyroid function, and inhibited local invasion in mouse thyroid cancer models expressing PAX8 - PPARG and were null for PTEN (PMID: 25069464).",
            "molecularProfile": {
                "id": 24799,
                "profileName": "PAX8 - PPARG PTEN del"
            },
            "therapy": {
                "id": 3125,
                "therapyName": "Pioglitazone",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4045,
                    "pubMedId": 25069464,
                    "title": "Pax-8-PPAR-\u03b3 fusion protein in thyroid carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25069464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with JQ1 reduced Myc levels, but did not inhibit growth of a mouse breast cancer cell line with PTEN deletion and over expression of MYC in culture (PMID: 26058079).",
            "molecularProfile": {
                "id": 26371,
                "profileName": "MYC over exp PTEN del"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with MS417 did not inhibit growth of a mouse breast cancer cell line with PTEN deletion and over expression of MYC in culture, and had modest effect on tumor growth in mouse allograft models (PMID: 26058079).",
            "molecularProfile": {
                "id": 26371,
                "profileName": "MYC over exp PTEN del"
            },
            "therapy": {
                "id": 3335,
                "therapyName": "MS417",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8592,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in increased tumor cell death and tumor shrinkage in mouse breast cancer cell line allograft models with PTEN deletion and MYC over expression, and demonstrated increased efficacy over either agent alone (PMID: 26058079).",
            "molecularProfile": {
                "id": 26371,
                "profileName": "MYC over exp PTEN del"
            },
            "therapy": {
                "id": 4774,
                "therapyName": "MS417 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8580,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse breast cancer cell line with over expression of MYC and PTEN deletion demonstrated resistance to Pictilisib (GDC-0941) in culture, and Pictilisib (GDC-0941) had modest effect on tumor growth in mouse allograft models (PMID: 26058079).",
            "molecularProfile": {
                "id": 26371,
                "profileName": "MYC over exp PTEN del"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6693,
                    "pubMedId": 26058079,
                    "title": "Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26058079"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) demonstrated limited inhibition of Akt phosphorylation and growth in bladder cancer cells harboring PIK3CA P124L and PTEN deletion in culture (PMID: 28808038).",
            "molecularProfile": {
                "id": 28746,
                "profileName": "PIK3CA P124L PTEN del"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9961,
                    "pubMedId": 28808038,
                    "title": "The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28808038"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2408,
            "profileName": "PTEN del",
            "profileTreatmentApproaches": [
                {
                    "id": 12442,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PTEN del"
                },
                {
                    "id": 12438,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PTEN del"
                },
                {
                    "id": 12439,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PTEN del"
                },
                {
                    "id": 12440,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PTEN del"
                },
                {
                    "id": 12441,
                    "name": "PIK3CB inhibitor",
                    "profileName": "PTEN del"
                }
            ]
        },
        {
            "id": 11800,
            "profileName": "KRAS mut PIK3CA mut PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15028,
            "profileName": "PIK3CB L1049R PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15029,
            "profileName": "PIK3CB amp PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20270,
            "profileName": "ERBB2 neg ESR1 neg PGR neg PIK3CA wild-type PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24369,
            "profileName": "PDGFB over exp PTEN del TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24799,
            "profileName": "PAX8 - PPARG PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26371,
            "profileName": "MYC over exp PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28746,
            "profileName": "PIK3CA P124L PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}